Literature DB >> 11672760

Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA.

D Prisco1, S Fedi, E Antonucci, M Capanni, L Chiarugi, M Chioccioli, M Falai, C Giglioli, R Abbate, G F Gensini.   

Abstract

Stent implantation after balloon dilation of coronary arteries has improved clinical prognosis in patients undergoing transluminal coronary angioplasty (PTCA), but late restenosis remains a relevant problem. A previous study has indicated that PAI-1 activity changes immediately after PTCA without stent implantation are predictive of clinical restenosis. The present study was aimed to investigate the early PAI-1 changes and fibrin formation in patients undergoing elective PTCA with stent implantation. PAI-1 activity and D-dimer plasma levels were evaluated in two groups of patients (G1 underwent only elective balloon PTCA and G2 underwent elective PTCA with stent implantation) before and after the procedure. At the end of the procedure, PAI-1 activity significantly decreased, while D-dimer levels significantly increased in both groups. Post-PTCA D-dimer levels in the group with stent implantation were significantly higher than in the other group (P<.05). In both groups of patients, the post-PTCA PAI-1 activity was higher in patients with subsequent clinical recurrence with restenosis (P<.005 in G1 and P<.0005 in G2) than in those without, whereas no differences were found in D-dimer levels. In conclusion, our results demonstrate that fibrin formation assessed by D-dimer levels is enhanced by stent implantation. However, this behaviour is not related, differently from PAI-1 changes, to subsequent occurrence of clinical restenosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672760     DOI: 10.1016/s0049-3848(01)00360-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting.

Authors:  R Marcucci; D Brogi; F Sofi; C Giglioli; S Valente; A Alessandrello Liotta; M Lenti; A M Gori; D Prisco; R Abbate; G F Gensini
Journal:  Heart       Date:  2005-07-01       Impact factor: 5.994

2.  Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty.

Authors:  Yelena Parfyonova; Irina Alekseeva; Olga Plekhanova; Alexander Deev; Elena Titaeva; Anatoly Dobrovolsky; Zufar Gabbasov; Anatoly Lyakishev; Vsevolod Tkachuk
Journal:  Heart Vessels       Date:  2013-09-22       Impact factor: 2.037

3.  Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents.

Authors:  Ailiman Mahemuti; Nicolas Meneveau; Marie-France Seronde; Francois Schiele; Vincent Descotes-Genon; Fiona Ecarnot; Marie-Cecile Blonde; Mariette Mercier; Evelyne Racadot; Jean-Pierre Bassand
Journal:  J Thromb Thrombolysis       Date:  2008-09-03       Impact factor: 2.300

Review 4.  Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

Authors:  Rohan Samarakoon; Paul J Higgins
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

Review 5.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

Authors:  Hunjoo Ha; Eun Y Oh; Hi B Lee
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

6.  Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  Mol Med Ther       Date:  2012-08-05

7.  Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.

Authors:  Tessa M Simone; Stephen P Higgins; Craig E Higgins; Michelle R Lennartz; Paul J Higgins
Journal:  J Mol Genet Med       Date:  2014-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.